Primary and secondary glioblastomas: From concept to clinical diagnosis

Neuro-Oncology

Volumn 1, Issue 1, 1999, Pages 44-51

  Kleihues, Paul ^a   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN MDM2; PROTEIN P16INK4A; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR PROTEIN;

ADULT; AGE DISTRIBUTION; BRAIN TUMOR; CELL TRANSFORMATION; CLASSIFICATION; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; MACROMOLECULE; MALE; MIDDLE AGED; NOMENCLATURE; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; REVIEW; SEX RATIO; TUMOR SUPPRESSOR GENE;

ADULT; AGE DISTRIBUTION; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DCC; GENES, P16; GENES, P53; GENES, RETINOBLASTOMA; GENOTYPE; GLIOBLASTOMA; HUMANS; LOSS OF HETEROZYGOSITY; MACROMOLECULAR SUBSTANCES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PHENOTYPE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RETINOBLASTOMA PROTEIN; SEX DISTRIBUTION; TERMINOLOGY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032601166     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1093/neuonc/1.1.44     Document Type: Article

References (89)

1. al-Sarraj, S., and Bridges, L.R. (1995) p53 immunoreactivity in astrocytomas and its relationship to survival. Br. J. Neurosurg. 9, 143-149.
2. Albarosa, R., Colombo, B.M., Roz, L., Magnani, I., Pollo, B., Cirenei, N., Giani, C., Conti, A.M., DiDonato, S., and Finocchiaro, G. (1996) Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. Am. J. Hum. Genet. 58, 1260-1267.
3. Ashley, D.M., and Bigner, D.D. (1997) Recent advances in the biology of cen-tral nervous system tumors. Curr. Opin. Neurol. 10, 445-451.
4. Barak, Y., Gottlieb, E., Juven-Gershon, T., and Oren, M. (1994) Regulation of mdm2 expression by p53: Alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8, 1739-1749.
5. Barker, F.G., II, Davis, R.L., Chang, S.M., and Prados, M.D. (1996) Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 77, 1161-1166.
6. Biernat, W., Kleihues, P., Yonekawa, Y., and Ohgaki, H. (1997a) Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J. Neuropathol. Exp. Neurol. 56, 180-185.
7. Biemat, W., Tohma, Y., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (1997b) Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta. Neuropathol. 94, 303-309.
8. 1. Cancer Res. 58, 29-33.
9. Burger, P.C., and Green, S.B. (1987) Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59, 1617-1625.
10. Burger, P.C., and Kleihues, P. (1989) Cytologic composition of the untreated glioblastoma with implications for evaluation of needle biopsies. Cancer 63, 2014-2023.
11. Burger, P.C., and Scheithauer, B.W. (1994) Tumors of the Central Nervous System. Atlas of tumor pathology, third series, fascicle 10. Washington: Armed Forces Institute of Pathology.
12. Burns, K.L., Ueki, K., Jhung, S.L., Koh, J., and Louis, D.N. (1998) Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J. Neuropathol. Exp. Neurol. 57, 122-130.
13. Claesson Welsh, L. (1994) Platelet-derived growth factor receptor signals. J. Biol. Chem. 269, 32023-32026.
14. Collins, V.P. (1995) Gene amplification in human gliomas. Glia 15, 289-296.
15. Dirks, P.B., and Rutka, J.T. (1997) Current concepts in neuro-oncology: The cell cycle - a review. Neurosurgery 40, 1000-1013.
16. Dropcho, E.J., and Soong, S.J. (1996) The prognostic impact of prior low grade histology in patients with anaplastic gliomas: A case-control study. Neurology 47, 684-690.
17. Duerr, E.-M., Rollbrocker, B., Hayashi, Y., Peters, N., Meyer-Puttlitz, B., Louis, D.N., Schramm, J., Wiestler, O.D., Parsons, R., Eng, C., and von Deimling, A. (1998) PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16, 2259-2264.
18. Ekstrand, A.J., Sugawa, N., James, C.D., and Collins, V.P. (1992) Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. U. S. A. 89, 4309-4313.
19. Fearon, E.R., Cho, K.R., Nigro, J.M., Kern, S.E., Simons, J.W., Ruppert, J.M., Hamilton, S.R., Preisinger, A.C., Thomas, G., Kinzler, K.W., Kinzler, K.W., and Vogelstein, B. (1990) Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247, 49-56.
20. Fults, D., and Pedone, C. (1993) Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme. Genes Chromosom. Cancer 7, 173-177.
21. Haffner, R., and Oren, M. (1995) Biochemical properties and biological effects of p53. Curr. Opin. Genet. Dev. 5, 84-90.
22. Hainaut, P. (1995) The tumor suppressor protein p53: A receptor to genotoxic stress that controls cell growth and survival. Curr. Opin. Oncol. 7, 76-82.
23. Hayashi, Y., Ueki, K., Waha, A., Wiestler, O.D., Louis, D.N., and von Deimling, A. (1997) Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol. 7, 871-875.
24. Heldin, C.H., and Westermark, B. (1990) Platelet-derived growth factor: Mechanism of action and possible in vivo function. Cell Regul. 1, 555-566.
25. Hermanson, M., Funa, K., Koopmann, J., Maintz, D., Waha, A., Westermark, B., Heldin, C.H., Wiestler, O.D., Louis, D.N., von Deimling, A., and Nister, M. (1996) Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res. 56, 164-171.
26. Kinzler, K.W., and Vogelstein, B. (1998) Landscaping the cancer terrain. Science 280, 1036-1037.
27. Kleihues, P., and Ohgaki, H. (1997) Genetics of glioma progression and the definition of primary and secondary glioblastoma. Brain Pathol. 7, 1131-1136.
28. Kleihues, P., Burger, P.C., Plate, K.H., Ohgaki, H., and Cavenee, W.K. (1997) Glioblastoma. In: Kleihues, P., and Cavenee, W.K. (Eds.), Pathology and Genetics of Tumours of the Nervous System. Lyon: International Agency for Research on Cancer, pp. 16-24.
29. Korkolopoulou, P., Christodoulou, P., Kouzelis, K., Hadjiyannakis, M., Priftis, A., Stamoulis, G., Seretis, A., and Thomas-Tsagli, E. (1997) MDM2 and p53 expression in gliomas: A multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br. J. Cancer 75, 1269-1278.
30. Kubo, Y., Urano, Y., Matsumoto, K., Ahsan, K., and Arase, S. (1997) Mutations of the INK4a locus in squamous cell carcinomas of human skin Biochem. Biophys. Res. Commun. 232, 38-41.
31. Lang, F.F., Miller, D.C., Koslow, M., and Newcomb, E.W. (1994) Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors. J. Neurosurg. 81, 427-436.
32. Lantos, P.L., VandenBerg, S.R., and Kleihues, P. (1996) Tumours of the Nervous System. In: Graham, D.I., and Lantos, P.L. (Eds.), Greenfield's Neuropathology. London: Arnold, pp. 583-879.
33. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S.H., Giovanella, B.C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M.H., and Parsons, R. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947.
34. Libermann, T.A., Nusbaum, H.R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M.D., Ullrich, A., and Schlessinger, J. (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313, 144-147.
35. Louis, D.N. (1994) The p53 gene and protein in human brain tumors. J. Neuropathol. Exp. Neurol. 53, 11-21.
36. Louis, D.N. (1997) A molecular genetic model of astrocytoma histopathology. Brain Pathol. 7, 755-764.
37. Louis, D.N., and Gusella, J.F. (1995) A tiger behind many doors: Multiple genetic pathways to maligant glioma. Trends Genet. 11, 412-415.
38. Louis, D.N., von Deimling, A., Chung, R.Y., Rubio, M.P., Whaley, J.M., Eibl, R.H., Ohgaki, H., Wiestler, O.D., Thor, A.D., and Seizinger, B.R. (1993) Comparative study of p53 gene and protein alterations in human astrocytic tumors. J. Neuropathol. Exp. Neurol. 52, 31-38.
39. Matsumoto, R., Tada, M., Nozaki, M., Zhang, C.L., Sawamura, Y., and Abe, H. (1998) Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res. 58, 609-613.
40. Meyer-Puttlitz, B., Hayashi, Y., Waha, A., Rollbrocker, B., Bostrom, J., Wiestler, O.D., Louis, D.N., Reifenberger, G., and von Deimling, A. (1997) Molecular genetic analysis of giant cell glioblastomas. Am. J. Pathol. 151, 853-857.
41. Nagane, M., Coufal, F., Lin, H., Bogler, O., Cavenee, W.K., and Huang, H.J.S. (1996) A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 56, 5079-5086.
42. Nelson, J.S., Tsukada, Y., Schoenfeld, D., Fulling, K., Lamarche, J., and Peress, N. (1983) Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 52, 550-554.
43. Newcomb, E.W., Madonia, W.J., Pisharody, S., Lang, F.F., Koslow, M., and Miller, D.C. (1993) A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol. 3, 229-235.
44. Newcomb, E.W., Cohen, H., Lee, S.R., Bhalla, S.K., Bloom, J., Hayes, R.L., and Miller, D.C. (1998) Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bd-2 genes. Brain Pathol. 8, 655-667.
45. Nigro, J.M., Baker, S.J., Preisinger, A.C., Jessup, J.M., Hostetter, R., Cleary, K., Bigner, S.H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F.S., Weston, A., Modali, R., Harris, C.C., and Vogelstein, B. (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342, 705-708. (Letter)
46. Nishikawa, R., Ji, X.D., Harmon, R.C., Lazar, C.S., Gill, G.N., Cavenee, W.K., and Huang, H.J. (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. U. S. A. 91, 7727-7731.
47. Ohgaki, H., Schauble, B., zur Hausen, A., von Ammon, K., and Kleihues, P. (1995) Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch. 427, 113-118.
48. Olson, D.C., Marechal, V., Momand, J., Chen, J., Romocki, C., and Levine, A.J. (1993) Identification and characterization of multiple MDM-2 proteins and MDM-2-p53 protein complexes. Oncogene 8, 2353-2360.
49. Peraud, A., Watanabe, K., Plate, K.H., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (1997) p53 mutations versus EGF receptor expression in giant cell glioblastomas. J. Neuropath. Exp. Neurol. 56, 1236-1241.
50. Picksley, S.M., and Lane, D.P. (1993) The p53-mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53? Bioessays 15, 689-690.
51. Pomerantz, J., Schreiber-Agus, N., Liegeois, N.J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.W., Cordon-Cardo, C., and DePinho, R.A. (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713-723.
52. Prigent, S.A., Nagane, M., Lin, H., Huvar, I., Boss, G.R., Feramisco, J.R., Cavenee, W. K., and Huang, H.S. (1996) Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J. Biol. Chem. 271, 25639-25645.
53. Rasheed, B.K., McLendon, R.E., Herndon, J.E., Friedman, H.S., Friedman, A.H., Bigner, D.D., and Bigner, S.H. (1994) Alterations of the TP53 gene in human gliomas. Cancer Res. 54, 1324-1330.
54. Rasheed, B.K., McLendon, R.E., Friedman, H.S., Friedman, A.H., Fuchs, H.E., Bigner, D.D., and Bigner, S.H. (1995) Chromosome 10 deletion mapping in human gliomas: A common deletion region in 10q25. Oncogene 10, 2243-2246.
55. Rasheed, B.K.A., Stenzel, T.T., McLendon, R.E., Parsons, R., Friedman, A.H., Friedman, H.S., Bigner, D.D., and Bigner, S.H. (1997) PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 57, 4187-4190.
56. Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E.E., and Collins, V.P. (1993) Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53, 2736-2739.
57. Reifenberger, J., Ring, G.U., Gies, U., Cobbers, L., Oberstrass, J., An, H.X., Niederacher, D., Wechsler, W., and Reifenberger, G. (1996) Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J. Neuropathol. Exp. Neurol. 55, 822-831.
58. Reyes-Mugica, M., Rieger-Christ, K., Ohgaki, H., Ekstrand, B.C., Helie, M., Kleinman, G., Yahanda, A., Fearon, E.R., Kleihues, P., and Reale, M.A. (1997) Loss of DCC expression and glioma progression. Cancer Res. 57, 382-386.
59. Russell, D.S., and Rubinstein, L.J. (1989) Pathology of Tumours of the Nervous System. Fifth edition. London: Edward Arnold.
60. Scherer, H.J. (1938) Structural development in gliomas. Am. J. Cancer, 34, 333-351.
61. _. (1940a) Cerebral astrocytomas and their derivatives. Am. J. Cancer 40, 159-198.
62. _. (1940b) The forms of growth in gliomas and their practical significance. Brain 63, 1-35.
63. _. (1940c) The pathology of cerebral gliomas. A critical review. J. Neurol. 3, 147-177.
64. Shiohara, M., Spirin, K., Said, J.W., Gombart, A.F., Nakamaki, T., Takeuchi, S., Hatta, Y., Morosetti, R., Tasaka, T., Seriu, T., Bartram, C., Miller, C.W., Tomonaga, M., and Koeffler, H.P. (1996) Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies. Leukemia 10, 1897-1900.
65. Sidransky, D., Mikkelsen, T., Schwechheimer, K., Rosenblum, M.L., Cavenee, W.K., and Vogelstein, B. (1992) Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature, 355, 846-847.
66. Sigalas, I., Calvert, A.H., Anderson, J.J., Neal, D.E., and Lunec, J. (1996) Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer. Nat. Med. 2, 912-917.
67. Sonoda, Y., Murakami, Y., Tominaga, T., Kayama, T., Yoshimoto, T., and Sekiya, T. (1996) Deletion mapping of chromosome 10 in human glioma. Jpn. J. Cancer Res. 87, 363-367.
68. Steck, P.A., Ligon, A.H., Cheong, P., Yung, W.K., and Pershouse, M.A. (1995) Two tumor suppressive loci on chromosome 10 involved in human glioblastomas. Genes Chromosomes Cancer 12, 255-261.
69. Steck, P.A., Pershouse, M.A., Jasser, S.A., Yung, W.K. A., Lin, H., Ligon, A.H., Langford, L.A., Baumgard, M.L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D.H.F., and Tavtigian, S.V. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet. 15, 356-362.
70. Sugawa, N., Ekstrand, A.J., James, C.D., and Collins, V.P. (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. U. S. A. 87, 8602-8606.
71. Tohma, Y., Gratas, C., Biernat, W., Peraud, A., Fukuda, M., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (1998a) PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J. Neuropath. Exp. Neurol. 57, 684-689.
72. Tohma, Y., Gratas, C., Van Meir, E.G., Desbaillets, I., Tenan, M., Tachibana, O., Kleihues, P., and Ohgaki, H. (1998b) Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J. Neuropath. Exp. Neurol. 57, 239-245.
73. Ueki, K., Ono, Y., Henson, J.W., Efird, J.T., von Deimling, A., and Louis, D.N. (1996) CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56, 150-153.
74. van Meyel, D.J., Ramsay, D.A., Casson, A.G., Keeney, M., Chambers, A.F., and Cairncross, J.G. (1994) p53 mutation, expression, and DNA ploidy in evolving gliomas: Evidence for two pathways of progression. J. Natl. Cancer Inst 86, 1011-1017.
75. Vogelstein, B., and Kinzler, K.W. (1993) The multistep nature of cancer. Trends Genet. 9, 138-141.
76. von Deimling, A., Louis, D.N., von Ammon, K., Petersen, I., Hoell, T., Chung, R.Y., Martuza, R.L., Schoenfeld, D.A., Yasargil, M.G., Wiestler, O.D., and Seizinger, B.R. (1992a) Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J. Neurosurg. 77, 295-301.
77. von Deimling, A., Louis, D.N., von Ammon, K., Petersen, I., Wiestler, O.D., and Seizinger, B.R. (1992b) Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res. 52, 4277-4279.
78. von Deimling, A., von Ammon, K., Schoenfeld, D., Wiestler, O.D., Seizinger, B.R., and Louis, D.N. (1993) Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol. 3, 19-26.
79. von Deimling, A., Nagel, J., Bender, B., Lenartz, D., Schramm, J., Louis, D.N., and Wiestler, O.D. (1994) Deletion mapping of chromosome 19 in human gliomas. Int J. Cancer 57, 676-680.
80. von Deimling, A., Louis, D.N., and Wiestler, O.D. (1995) Molecular pathways in the formation of gliomas. Glia 15, 328-338.
81. Wang, S.I., Puc, J., Li, J., Bruce, J.N., Cairns, P., Sidransky, D., and Parsons, R. (1997) Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 57, 4183-4186.
82. Watanabe, K., Tachibana, O., Sato, K., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6, 217-224.
83. Watanabe, K., Sato, K., Biernat, W., Tachibana, O., von Ammon, K., Ogata, N., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (1997a) Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin. Cancer Res. 3, 523-530.
84. Watanabe, K., Tachibana, O., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (1997b) Role of gemistocytes in astrocytoma progression. Lab. Invest 76, 277-284.
85. Winger, M.J., Macdonald, D.R., and Cairncross, J.G. (1989) Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J. Neurosurg. 71, 487-493.
86. Wong, A.J., Ruppert, J.M., Bigner, S.H., Grzeschik, C.H., Humphrey, P.A., Bigner, D. S., and Vogelstein, B. (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. U. S. A. 89, 2965-2969.
87. Zauberman, A., Flusberg, D., Haupt, Y., Barak, Y., and Oren, M. (1995) A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Adds. Res. 23, 2584-2592.
88. Zhang, Y., Xiong, Y., and Yarbrough, W.G. (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725-734.
89. Zulch, K.J. (1986). Brain Tumors. Their Biology and Pathology. Third edition. Berlin, Springer Verlag.